These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32314355)

  • 1. The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma.
    Liang L; He Y; Wang H; Zhou H; Xiao L; Ye M; Kuang Y; Luo S; Zuo Y; Feng P; Yang C; Cao W; Liu T; Roy M; Xiao X; Liu J
    Br J Haematol; 2020 Oct; 191(1):62-76. PubMed ID: 32314355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
    Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
    Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells.
    Li C; Shen Q; Zhang P; Wang T; Liu W; Li R; Ma X; Zeng X; Yin Y; Tao K
    J Exp Clin Cancer Res; 2021 Oct; 40(1):315. PubMed ID: 34625086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775.
    Hauge S; Macurek L; Syljuåsen RG
    Cell Cycle; 2019 Apr; 18(8):834-847. PubMed ID: 30943845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.
    Kreahling JM; Foroutan P; Reed D; Martinez G; Razabdouski T; Bui MM; Raghavan M; Letson D; Gillies RJ; Altiok S
    PLoS One; 2013; 8(3):e57523. PubMed ID: 23520471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
    Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
    Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.
    Van Linden AA; Baturin D; Ford JB; Fosmire SP; Gardner L; Korch C; Reigan P; Porter CC
    Mol Cancer Ther; 2013 Dec; 12(12):2675-84. PubMed ID: 24121103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.
    Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S
    Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
    Lewis CW; Bukhari AB; Xiao EJ; Choi WS; Smith JD; Homola E; Mackey JR; Campbell SD; Gamper AM; Chan GK
    Cancer Res; 2019 Dec; 79(23):5971-5985. PubMed ID: 31594837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
    Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
    Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
    Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
    Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
    Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
    Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan.
    Yin Y; Shen Q; Tao R; Chang W; Li R; Xie G; Liu W; Zhang P; Tao K
    Mol Med Rep; 2018 Feb; 17(2):3344-3349. PubMed ID: 29257266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress.
    Lindemann A; Patel AA; Tang L; Tanaka N; Gleber-Netto FO; Bartels MD; Wang L; McGrail DJ; Lin SY; Frank SJ; Frederick MJ; Myers JN; Osman AA
    Mol Cancer Ther; 2021 Jul; 20(7):1257-1269. PubMed ID: 33947685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
    Murakami K; Kita Y; Sakatani T; Hamada A; Mizuno K; Nakamura K; Takada H; Matsumoto K; Sano T; Goto T; Akamatsu S; Saito R; Tsuruyama T; Ogawa O; Kobayashi T
    Cancer Sci; 2021 Sep; 112(9):3669-3681. PubMed ID: 34212455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.
    Magnussen GI; Emilsen E; Giller Fleten K; Engesæter B; Nähse-Kumpf V; Fjær R; Slipicevic A; Flørenes VA
    BMC Cancer; 2015 Jun; 15():462. PubMed ID: 26054341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
    Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases.
    Chen ZL; Xie C; Zeng W; Huang RQ; Yang JE; Liu JY; Chen YJ; Zhuang SM
    Signal Transduct Target Ther; 2024 Jul; 9(1):181. PubMed ID: 38992067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.